Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T09538
|
||||
| Former ID |
TTDS00256
|
||||
| Target Name |
Alkaline phosphatase, tissue-nonspecific
|
||||
| Gene Name |
ALPL
|
||||
| Synonyms |
AP-TNAP; Liver/bone/kidney isozyme; TNSALP; ALPL
|
||||
| Target Type |
Successful
|
||||
| Disease | Anthelmintic [ICD10: B89] | ||||
| Colon cancer [ICD9: 153, 154; ICD10: C50] | |||||
| Genetic disease [ICD10: Q00-Q99] | |||||
| Function |
This isozyme may play a role in skeletal mineralization.
|
||||
| BioChemical Class |
Phosphoric monoester hydrolases
|
||||
| Target Validation |
T09538
|
||||
| UniProt ID | |||||
| EC Number |
EC 3.1.3.1
|
||||
| Sequence |
MISPFLVLAIGTCLTNSLVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGD
GMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCG VKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAH SADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDE KARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELN RNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIG QAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPG YKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYV PHVMAYAACIGANLGHCAPASSAGSLAAGPLLLALALYPLSVLF |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Asfotase alfa | Drug Info | Approved | Genetic disease | [1] |
| Levamisole | Drug Info | Approved | Anthelmintic | [2] | |
| Levamisole | Drug Info | Withdrawn from market | Colon cancer | [3], [4] | |
| Modulator | Asfotase alfa | Drug Info | [5] | ||
| Inhibitor | Levamisole | Drug Info | [6] | ||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Folate biosynthesis | ||||
| Metabolic pathways | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| PathWhiz Pathway | Vitamin B6 Metabolism | ||||
| WikiPathways | Endochondral Ossification | ||||
| BDNF signaling pathway | |||||
| AGE/RAGE pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01176266) Open-Label Study of Asfotase Alfa in Infants and Children ??5 Years of Age With Hypophosphatasia (HPP). U.S. National Institutes of Health. | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 3 | New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. | ||||
| REF 4 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7210). | ||||
| REF 5 | Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13. | ||||
| REF 6 | Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.